These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36877775)

  • 81. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
    Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
    J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
    Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
    Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
    Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
    Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
    Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
    Chen JR; Yao Y; Xu HZ; Qin ZY
    Medicine (Baltimore); 2016 Mar; 95(9):e2583. PubMed ID: 26945349
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Detection of Isocitrate Dehydrogenase Mutated Glioblastomas Through Anomaly Detection Analytics.
    Taha B; Li T; Boley D; Chen CC; Sun J
    Neurosurgery; 2021 Jul; 89(2):323-328. PubMed ID: 33887763
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
    de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
    Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
    Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
    Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
    [TBL] [Abstract][Full Text] [Related]  

  • 89. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.
    Álvarez-Torres MDM; Fuster-García E; Juan-Albarracín J; Reynés G; Aparici-Robles F; Ferrer-Lozano J; García-Gómez JM
    BMC Cancer; 2022 Jan; 22(1):40. PubMed ID: 34991512
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype.
    Sohn B; Park K; Ahn SS; Park YW; Choi SH; Kang SG; Kim SH; Chang JH; Lee SK
    J Neurooncol; 2023 Sep; 164(2):341-351. PubMed ID: 37689596
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant.
    Sohn B; An C; Kim D; Ahn SS; Han K; Kim SH; Kang SG; Chang JH; Lee SK
    J Neurooncol; 2021 Dec; 155(3):267-276. PubMed ID: 34648115
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation.
    Ishi Y; Yamaguchi S; Okamoto M; Sawaya R; Endo S; Motegi H; Terasaka S; Tanei ZI; Hatanaka KC; Tanaka S; Fujimura M
    Brain Tumor Pathol; 2022 Jul; 39(3):162-170. PubMed ID: 35362874
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Integrated molecular characterization of IDH-mutant glioblastomas.
    Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.
    Sim HW; Lorrey S; Khasraw M
    Curr Neurol Neurosci Rep; 2023 Jun; 23(6):263-276. PubMed ID: 37154886
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas.
    Hsieh KL; Chen CY; Lo CM
    Oncotarget; 2017 Jul; 8(28):45888-45897. PubMed ID: 28526813
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Characteristics and Prognosis of Tumor-Related Epilepsy During Tumor Evolution in Patients With
    Pallud J; Roux A; Moiraghi A; Aboubakr O; Elia A; Guinard E; Oppenheim C; Tauziede-Espariat A; Parraga E; Gavaret M; Chrètien F; Huberfeld G; Zanello M
    Neurology; 2024 Jan; 102(1):e207902. PubMed ID: 38165369
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Prognostic significance of MRI contrast enhancement in newly diagnosed glioblastoma, IDH-wildtype according to WHO 2021 classification.
    Roux A; Elia A; Hudelist B; Benzakoun J; Dezamis E; Parraga E; Moiraghi A; Simboli GA; Chretien F; Oppenheim C; Zanello M; Pallud J
    J Neurooncol; 2024 Jun; ():. PubMed ID: 38913230
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The effect of p53 on the activity of NRF2 and NDRG2 genes through apoptotic pathway in IDH-wildtype glioblastoma.
    Kurdi M; Baeesa S; Fadul MM; Alkhotani A; Alkhayyat S; Karami MM; Alsinani T; Katib Y; Fathaddin AA; Faizo E; Lary AI; Almansouri M; Maghrabi Y; Alyousef MA; Addass B
    Pathol Res Pract; 2024 Feb; 254():155118. PubMed ID: 38241776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.